Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.

A trio of experts discuss the challenges of diagnosing and managing paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening disorder.

Cardiovascular risk factors increase the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms, a study found.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.